#### **National Institute for Health & Clinical Excellence**

## **CS Short Clinical Guideline**

## Guideline Development Group (GDG) meeting one

29<sup>th</sup> & 30<sup>th</sup> April 2010

Ribble & Mersey, City Tower, Piccadilly Plaza, M1 4BD

#### **GROUP MEMBERSHIP & ACTION LIST**

In Attendance	
GDG Members	
Peter Howdle (Chair) (PH)	Julie D'Silva (JD)
Carol Makin (CM)	
Tracey Cole (TC)	
Bruce Fox (BF)	
Elaine Trump (ET)	
Matt Rutter (MR)	
Marco Novelli (MN)	
Janusz Jankowski (JS)	
NICE Staff	
Michael Heath (MH)	Yaminah Rajput (YR)
Vicky Kelly (VK)	Ann Greenwood (AG)
Tarang Sharma (TS)	
Jonathan Nyong (JN)	
Caroline Keir(CK)	
Louise Foster (LF)	
Prashanth Kandaswamy (PK)	
Kim Jeong (KJ)	
Apologies:	
Wendy Atkin (WA)	

#### REPORT OF DISCUSSIONS AT THE MEETING

29<sup>th</sup> April 2010

# 1.1 Agenda item 1: Introductions, Objectives, Declaration of Interests & Review of GDG 1

PH opened the meeting by welcoming members to the third guideline development group (GDG) meeting

PH ran through the main aims and objectives for the group. PH asked the group to declare any interests.

## 1.2 Agenda item 2: Patient Information

The group were shown the draft recommendations from the patient information session and discussed/reviewed the evidence associated with it. The group made some changes to the recommendations in light of this discussion

#### 1.3 Agenda Item 3: Health Economics Polyps

The group were presented with final polyp model.

#### 1.4 Agenda item 4: Key clinical question 3 Polyps - Evidence

The group reviewed the evidence and agreed the evidence statements for the polyps questions.

#### 1.5 Agenda item 5: Key clinical question 3 Polyps - Recommendations

The group made recommendations on frequency of surveillance for people with polyps.

#### 1.6 Agenda item 6: Health Economics IBD

The group were shown the current model for IBD HE and asked to agree thresholds for the final version for various parts of the model

#### 1.7 Agenda item 7 Key clinical question 3 IBD - Evidence

The group reviewed the evidence and agreed the evidence statements for the IBD questions

#### 1.8 Agenda item 8 Key clinical question 3 IBD – Recommendations

The group made recommendations on frequency of surveillance for people with IBD

## 30<sup>th</sup> April 2010

#### 1.9 Agenda item 1: Review of day 1

PH ran through the previous days discussions

#### 1.10 Agenda item 2: Health Economics Final Results

The Health Economists presented their final results

## 1.11 Agenda item 3: Care Pathway

The group discussed the two care pathways for inclusion in the guideline

## 1.12 Agenda item 4: Review of all Recommendations made

The group reviewed and amended all the draft recommendations before consultation

## 1.13 Agenda item 5: Research Recommendations

The group were asked to suggest areas for further research within the scope of this guideline

## 1.14 Agenda item 6:Next Steps

The group were told of the next steps in development which include a consultation period for external stakeholders to make comment. The group were reminded of the next meeting date Friday 9<sup>th</sup> July in Manchester

## 1.15 Agenda item 7: AOB

None